BREAKING NEWS – A NEW REGULARY STEP IN THE US – Broader access to six key peptides including BPC-157 and TB-500

A MAJOR STEP FOR PEPTIDE MEDICINE IN THE US

US Health Secretary Robert F. Kennedy Jr. has introduced an interim policy allowing licensed pharmacies and physicians to compound six previously restricted peptides under specific conditions.

The objective?

To expand access to certain peptide therapies while reducing reliance on potentially unsafe, unregulated products.

*An important regulatory development but not FDA approval.

6 PEPTIDES AT THE CENTER OF THIS DECISION

• BPC-157
• Epitalon
• KPV
• MOTS-c
• Semax
• TB-500

WHY THIS NEWS MATTERS TO ME

For the past 18 years, I have explored the clinical applications of peptides, particularly in longevity and hormone medicine.

My experience has shown me the importance of studying their potential across several areas:

• Longevity and healthy aging
• Tissue repair and recovery
• Metabolic and cardiovascular health
• Cognitive function
• Inflammation management

I believe peptides deserve serious scientific attention, with careful consideration of their benefits, limitations, and safety.

18 YEARS OF EXPERIENCE IN PEPTIDE MEDICINE

Throughout my career, I have worked with numerous peptides and contributed to international medical education.

My longstanding collaboration with Professor Khavinson has also allowed me to deepen my expertise in Russian bioregulator peptides.

My approach combines:

• Clinical experience: Practical knowledge of prescribing protocols.
• Scientific research: Critical evaluation of published studies.
• Medical education: Sharing knowledge about indications, dosage, treatment duration, and safety.

My objective has always been to bridge scientific research and responsible clinical practice.

THE FUTURE OF PEPTIDE MEDICINE IS EVOLVING

From BPC-157 and Semax to Selank, Cerebrolysin, SS-31, and many others, I continue to follow and explore the therapeutic potential of peptides.

After 18 years of experience in Peptides, I believe we are only beginning to understand their possibilities.

Through my work and the Hertoghe Medical School, I aim to help physicians better understand peptide therapies, their scientific foundations, potential applications, and limitations.